Shanghai Bintie Biotechnology Co., Ltd. is a cutting-edge clinical-stage biotech company leading the way in developing a new type of immunocyte preparation that specifically targets solid tumors. The company's founder commands international influence in the field of tumor immunology, with several immunotherapy drugs, originally developed in the United States, currently in the clinical trial stage.
The company's unwavering long-term objective is to spearhead the development of a pioneering series of TCR products to effectively address recurrent and refractory malignant tumors, such as pancreatic cancer. Our mission encompasses the identification of TCRs that recognize shared cancer driver gene mutations and tumor neoantigens, the integration of personalized and universal cell therapy products, as well as the streamlining of the preparation cycle of cell therapy products, all with the ultimate goal of enhancing the effectiveness and accessibility of cell therapy.